ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Oramed Pharmaceuticals Commences Phase 1b Clinical Trials Tests Its Oral Insulin Capsule On Healthy Human Volunteers
Oramed Pharmaceuticals, Inc.
(OTCBB: ORMP ), a developer of oral delivery
systems, has begun Phase 1B clinical trials for its oral insulin capsule.
This Phase 1B trial is focused on finding the optimal dosage for the
formulation of Oramed's proprietary oral insulin delivery technology. The
study utilizes healthy human volunteers in order to determine the final
formulation of the oral insulin product. This trial is a continuation of
Oramed's successfully completed Phase 1A trials, which were conducted on
healthy volunteers
"Oramed is excited to move forward with our lead drug candidate,"
commented Nadav Kidron, Chief Executive Officer of Oramed. "This phase of
the trial, following the successful completion of our Phase 1A trials, is
a significant milestone for Oramed and for our oral insulin product. We
are pleased to be one step closer to our goal of offering the many
diabetes patients around the world a viable oral insulin solution."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals' is an Israeli-based company focused on the
development of oral delivery solutions based on proprietary technology.
Diabetes is one of the most rapidly growing diseases in the world and is
one that requires constant and often unpleasant monitoring and drug
therapy regimens. Oramed is currently developing an orally ingestible
insulin capsule for the treatment of diabetes. The Company is also
pursuing the development of oral delivery solutions for other drugs and
vaccines. For more information please visit our website at:
http://www.oramed.com.
Legal Notice and Forward Looking Statements For Oramed Pharmaceuticals
Certain of the statements contained in this press release, including the
statement "the Company's goal is for the completion of formal phase I
studies by the 3rd quarter of 2008", are forward-looking statements
which involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the
Company, or industry results, to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Please refer to the Company's filings with
the Securities and Exchange Commission for a comprehensive list of risk
factors that could cause actual results, performance or achievements of
the Company to differ materially from those expressed or implied in such
forward-looking statements. The Company undertakes no obligation to
update or revise any forward-looking statements.
Oramed Pharmaceuticals
Oramed Pharmaceuticals Commences studiile clinice de fazã 1b Teste ei oralã Insulina Capsule Pe sãnãtoasã Umane Voluntari - Oramed Pharmaceuticals Commences Phase 1b Clinical Trials Tests Its Oral Insulin Capsule On Healthy Human Volunteers - articole medicale engleza - startsanatate